Search Results

IBM is notifying Janssen CarePath customers and users of an incident involving unauthorized access to personal information contained within a database used on the Janssen CarePath platform, a patient support platform that offers savings options and other patient support resources.

Today, Cleveland Clinic and IBM (NYSE: IBM) officially unveiled the first deployment of an onsite private sector IBM-managed quantum computer in the United States.

Moderna, Inc. and IBM (NYSE:IBM) today announced an agreement under which Moderna will explore next generation technologies including quantum computing and artificial intelligence to advance and accelerate mRNA research and science.

SPIE, the international society for optics and photonics, and IBM Quantum have selected Wesley Sims, an assistant professor of physics at Morehouse College, as this year’s recipient of the IBM-SPIE HBCU Faculty Accelerator Award in Quantum Optics and Photonics.

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the completion of enrollment of the registrational Phase 2/3 MUSCLE clinical trial evaluating ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM).

, IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery.

Biorasi , a leading global full-service contract research organization (CRO), announced today that they have selected IBM Watson Health (IBM) as a preferred vendor. This relationship with IBM Watson Health expands Biorasi’s capabilities in clinical trial execution and management through IBM’s Clinical Development (ICD) platform – a clinical data management system (CDMS) designed to help bring efficiency and speed to the clinica

Today, Moderna (Nasdaq: MRNA) and IBM (NYSE: IBM) announced their intentions to explore technologies, including artificial intelligence, blockchain and hybrid cloud, that could help support smarter COVID-19 vaccine management.

Elucid Bioimaging Inc. (“Elucid Bio”) today announced that vascuCAP, Elucid Bio’s AI-enabled software for evaluating atherosclerotic plaque stability from CTA, has been added to the IBM Imaging AI Marketplace, an IBM Watson Health® solution.